Ischemic Stroke News and Research

RSS

Merci Retriever receives Shonin approval in Japan

Concentric Medical, Inc., the global leader in devices for clot removal in ischemic stroke patients, today announced that the Merci Retriever, Merci Microcatheter, and Merci Balloon Guide Catheter have received Shonin approval in Japan.

4 May 2010

ev3's first-quarter 2010 net sales up 21%

ev3 Inc., a global endovascular device company, today reported financial results for its fiscal first quarter and updated financial guidance for 2010. ev3's net sales totaled $123.9 million in the first quarter of 2010 compared to $100.4 million in the same quarter of the prior year. Excluding $2.9 million of positive impact due to foreign currency exchange rates, net sales increased 21% versus the prior year quarter.

29 Apr 2010

Talecris Biotherapeutics first-quarter net income increases 35.6% to $45.3 million

Talecris Biotherapeutics Holdings Corp. today announced its financial results for the three months ended March 31, 2010, and filed its first quarter 2010 Form 10-Q with the U.S. Securities and Exchange Commission (SEC).

29 Apr 2010

Merck disappointed with Supreme Court affirming lower court's ruling in federal securities class action suit

Merck announced today that it is disappointed with the U.S. Supreme Court's decision to affirm a lower court's ruling on when the statute of limitations began to run in a federal securities class action against the company and certain of its officers and directors. The effect of the ruling is to return the case to federal district court in New Jersey for further proceedings.

28 Apr 2010

19.6% of completed stroke trials not published in full

An investigation into unpublished stroke research data has revealed that 19.6% of completed clinical trials, which could potentially influence patient care, are not published in full. Researchers writing in BioMed Central's open access journal Trials describe how these unpublished studies included more than 16,000 participants and tested 89 different interventions.

24 Apr 2010

Red wine consumption may protect brain from stroke damage, say Johns Hopkins researchers

Researchers at Johns Hopkins say they have discovered the way in which red wine consumption may protect the brain from damage following a stroke.

22 Apr 2010

Stemedica receives FDA IND approval for ischemic stroke clinical trial using allogeneic stem cells

Stemedica Cell Technologies, Inc., a world leader in stem cell research and manufacturing, announced that the U.S. Food and Drug Administration (FDA) approved an Investigational New Drug (IND) for a clinical trial for ischemic stroke using Stemedica's high potency proprietary allogeneic stem cells (adult human).

21 Apr 2010

Reverse Medical signs strategic partnership agreement with Getz Bros.

Reverse Medical Corporation today announced it has entered into a strategic partnership agreement with Getz Bros. & Company, Inc., for distribution of Reverse Medical devices throughout the Pacific Rim. Getz is an international marketing and medical distribution services company with over 50 offices in 24 countries around the world, and has an excellent reputation for global distribution.

7 Apr 2010

Young adults with hyperthyroidism face increase risk of stroke

Young adults with overactive thyroid face a 44 percent increased risk of stroke compared to those with normal thyroid function, according to a study reported in Stroke: Journal of the American Heart Association.

3 Apr 2010

Reverse Medical closes Series-B private equity financing

Reverse Medical Corporation announced today the closing of their Series-B private equity financing. The Company raised $14 million from new investors Wexford Capital, Getz Bros., BioStar Ventures, Early Stage Partners and Emergent Medical Partners.

31 Mar 2010

Mexican-American women les likely to use emergency medical services for stroke symptoms

Mexican Americans are 40 percent less likely than non-Hispanic whites to call 9-1-1 and be taken to the hospital via ambulance for stroke - resulting in medical treatment delays - according to a new study reported in Stroke: Journal of the American Heart Association.

26 Mar 2010

Stemedica files IND for trial using allogeneic mesenchymal bone marrow cells in patients with ischemic stroke

Stemedica Cell Technologies, Inc. (Stemedica), a world leader in stem cell research and manufacturing, announced that it has filed an Investigative New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a clinical trial. The trial will assess the safety, tolerability and efficacy of Stemedica's high potency proprietary allogeneic mesenchymal bone marrow-derived stem cells (adult human) as a treatment for ischemic stroke.

19 Mar 2010

Clinical research trial of new treatment to restore brain cells damaged by stroke passes safety stage

A clinical research trial of a new treatment to restore brain cells damaged by stroke has passed an important safety stage, according to the UC Irvine neurologist who led the effort.

11 Mar 2010

Patients taking warfarin who develop acute stroke more likely to experience brain hemorrhage

Patients already taking warfarin who develop an acute stroke appear more likely to experience a brain hemorrhage following treatment with an intravenous clot-dissolving medication, even if their blood clotting function appears normal, according to a report posted online today that will appear in the May print issue of Archives of Neurology, one of the JAMA/Archives journals.

9 Mar 2010

Thymosin beta 4 improves neurological functional outcome

REGENERX BIOPHARMACEUTICALS, INC. announced that a research team from the Henry Ford Hospital in Detroit, MI reported that Thymosin beta 4 (Tβ4), administered to rats one day after embolic stroke, improved neurological functional outcome compared to control animals.

6 Mar 2010

Study indicates ocular shingles may increase stroke risk

Having a shingles infection that affects the eyes may increase the risk of stroke, according to new research published in the March 3, 2010, online issue of Neurology®, the medical journal of the American Academy of Neurology.

4 Mar 2010

FiberNet EPS has 97.5% success rate in patients undergoing CAS: EPIC study

A multicenter EPIC (FiberNet- Embolic Protection System in Carotid Artery Stenting Trial) study found that the FiberNet Embolic Protection System (EPS) had a 97.5% success rate when used in patients undergoing carotid artery stenting (CAS). Full findings are published early online in Catheterization and Cardiovascular Interventions, the official journal of The Society for Cardiovascular Angiography and Interventions.

1 Mar 2010

Dabigatran as effective as warfarin in preventing subsequent strokes among atrial fibrillation patients

The drug dabigatran was as effective as the currently recommended drug – warfarin – in preventing a subsequent stroke among people with atrial fibrillation and prior stroke or transient ischemic attack – and it did so with less bleeding according to late-breaking science presented at the American Stroke Association's International Stroke Conference 2010.

27 Feb 2010

Prevention of recurrent strokes: Antiplatelet drug cilostazol effective and safer than aspirin

The antiplatelet drug cilostazol — used in the United States to treat leg pain associated with peripheral vascular disease — was more effective and safer than aspirin at preventing recurrent strokes in a Japanese trial presented as late-breaking science at the American Stroke Association's International Stroke Conference 2010.